Blog
Relatlimab: Unlocking the Potential of LAG-3 Inhibition in Cancer Research
Quick Facts About RelatlimabWhat is Relatlimab?Relatlimab is a monoclonal antibody that targets LAG-3 (Lymphocyte Activation Gene-3), a key immune checkpoint involved in T-cell regulatio
…
29th Jan 2025
Bevacizumab: Mechanism, Clinical Applications, and Biosimilar Insights
Quick Facts About BevacizumabWhat is Bevacizumab?Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis (the formation of ne
…
29th Jan 2025
Patritumab Deruxtecan: Mechanism, Clinical Applications, and Biosimilar Advances
Quick Facts About Patritumab DeruxtecanWhat is Patritumab Deruxtecan?Patritumab Deruxtecan (HER3-DXd) is an investigational antibody-drug conjugate (ADC) targeting HER3, a receptor impli
…
29th Jan 2025
Ruplizumab: Unveiling the Role of Anti-CD47 in Cancer Research
Quick Facts About RuplizumabWhat is Ruplizumab?Ruplizumab is an investigational monoclonal antibody designed to target CD47, a protein that helps cancer cells evade immune detection.What
…
29th Jan 2025
Brodalumab: A Breakthrough in IL-17 Receptor Blockade for Psoriasis and Beyond
Quick Facts About BrodalumabWhat is Brodalumab?Brodalumab is a monoclonal antibody that targets the IL-17 receptor to treat immune-mediated conditions like moderate-to-severe plaque psor
…
29th Jan 2025
Adalimumab: Mechanism, Clinical Applications, and the Role of Biosimilars
Quick Facts About AdalimumabWhat is Adalimumab?Adalimumab is a fully human monoclonal antibody designed to neutralize tumor necrosis factor-alpha (TNF-α), a key cytokine involved in infl
…
29th Jan 2025
Cetuximab: A Revolutionary Drug in Cancer Therapy
Quick Facts About CetuximabWhat is Cetuximab?Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), widely used in cancer therapy.How does Cetuximab wo
…
29th Jan 2025
Utomilumab: Advancing Immuno-Oncology Research
Quick Facts About UtomilumabWhat is Utomilumab?Utomilumab is a monoclonal antibody targeting 4-1BB (CD137), a co-stimulatory receptor on T-cells, designed to enhance anti-tumor immunity.
…
29th Jan 2025
Labetuzumab: Revolutionizing Cancer Research with Targeted Therapies
Quick Facts About LabetuzumabWhat is Labetuzumab?Labetuzumab is a monoclonal antibody targeting CEACAM5, a protein overexpressed in various cancers, primarily colorectal carcinoma.How do
…
29th Jan 2025
Enapotamab: Advancing Cancer Research with Innovative Therapeutics
Quick Facts About EnapotamabWhat is Enapotamab?Enapotamab is an experimental antibody-drug conjugate (ADC) developed to target tumor cells selectively, offering new hope in cancer treatm
…
29th Jan 2025
Fezakinumab: Exploring Its Mechanism and Clinical Potential
Quick Facts About FezakinumabWhat is Fezakinumab?Fezakinumab is a human IgG1-lambda monoclonal antibody that targets interleukin-22 (IL-22), a cytokine involved in inflammatory responses
…
29th Jan 2025
Ianalumab: Exploring Its Mechanism, Clinical Applications, and Research Potential
Quick Facts About IanalumabWhat is Ianalumab?Ianalumab is a monoclonal antibody currently being investigated for its potential in treating autoimmune diseases, particularly lupus and imm
…
28th Jan 2025
Belimumab: Unveiling Its Role in Lupus and Beyond
Quick Facts About BelimumabWhat is Belimumab?Belimumab is a monoclonal antibody used to treat systemic lupus erythematosus (SLE), an autoimmune disease. It is marketed under the brand na
…
28th Jan 2025
Onvatilimab: Redefining the Role of Anti-CD47 in Cancer Research
Quick Facts About OnvatilimabWhat is Onvatilimab?Onvatilimab is a monoclonal antibody targeting CD47, often referred to as the "don't eat me" signal, which is overexpressed on many cance
…
27th Jan 2025
Zolbetuximab: A Breakthrough in Targeting Claudin 18.2 for Cancer Treatment
Quick Facts About ZolbetuximabWhat is Zolbetuximab?Zolbetuximab is a monoclonal antibody that targets Claudin 18.2, a protein overexpressed in gastric and pancreatic cancers, enhancing t
…
27th Jan 2025
Tigatuzumab: Advancing Cancer Research with Targeted Therapies
Quick Facts About TigatuzumabWhat is Tigatuzumab?Tigatuzumab is a monoclonal antibody that targets the death receptor 5 (DR5) pathway, inducing apoptosis in cancer cells.What is the mech
…
23rd Jan 2025
Basiliximab: Mechanism, Clinical Applications, and Research Advancements
Quick Facts About BasiliximabWhat is Basiliximab?Basiliximab is a monoclonal antibody targeting the CD25 subunit of the IL-2 receptor, primarily used to prevent organ transplant rejectio
…
22nd Jan 2025
Avizakimab: Unveiling the Role of Anti-CD47 in Cancer Research
Quick Facts About AvizakimabWhat is Avizakimab?Avizakimab is a monoclonal antibody designed to target the CD47 protein, a key checkpoint in immune regulation, particularly in cancer ther
…
21st Jan 2025
Tarextumab: Unlocking the Potential of Cancer Therapeutics
Quick Facts About TarextumabWhat is Tarextumab?Tarextumab is a novel therapeutic antibody designed to target the Notch signaling pathway, which plays a crucial role in tumor progression
…
21st Jan 2025
Murlentamab: Revolutionizing Cancer Research with Targeted Therapy
Quick Facts About MurlentamabWhat is Murlentamab?Murlentamab is a novel monoclonal antibody designed to target CD47, a "don’t eat me" signal that helps cancer cells evade the immune syst
…
21st Jan 2025
Sacituzumab: Exploring its Role in Cancer Research and the Rise of Biosimilars
Key Facts About SacituzumabWhat is Sacituzumab?Sacituzumab is an antibody-drug conjugate (ADC) that targets the tumor-associated antigen Trop-2, used to treat various cancers, including
…
16th Jan 2025
Ipilimumab and Nivolumab: Advancing Research on CTLA-4 in Cancer Therapy
What You Need to Know About IpilimumabWhat is Ipilimumab?Ipilimumab is a monoclonal antibody that targets CTLA-4, a protein involved in downregulating the immune system, to boost the bod
…
16th Jan 2025
Amatuximab: Exploring Mesothelin-Targeted Therapy for Cancer Research
What You Need to Know About AmatuximabIs Amatuximab safe?Amatuximab has shown a manageable safety profile in clinical trials, with most side effects being mild to moderate. Severe advers
…
15th Jan 2025
Iscalimab: Advancing Research in Autoimmune Diseases and Transplantation
What You Need to Know About IscalimabWhat is Iscalimab?Iscalimab (CFZ533) is a monoclonal antibody targeting CD40, a key protein involved in immune system regulation.What is the mechanis
…
15th Jan 2025